Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium
News provided byGenetic Technologies Ltd
Jan 24, 2023, 8:00 AM ET
MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce a poster presentation by Dr Erika Spaeth at the prestigious American Society of Clinical Oncology Gastroenterology Cancer Symposium in San Francisco last weekend. The Poster titled “Improvement of a clinical colorectal cancer risk prediction model integrating polygenic risk” was authored by GTG’s Science Team including Erika Spaeth, Aviv Gafni, Richard Allman and Gillian Dite.
- The poster demonstrates improved performance, identifying patients at risk of developing colorectal cancer by expanding number of SNPs from 45 to 144.
- The patients in the top risk category showed a 27% improvement compared with the 45 SNP geneType model.
- The improved performance was consistent across multiple genetic ancestries, greatly improving the utility of the test leading to increased surveillance in high risk patients.
- The poster builds on an earlier publication by GTG that validated the geneType model, focusing on its ability to stratify patients at higher risk of developing one of the world’s most common cancers.
The poster demonstrated a significant improvement in predicting a patient’s risk of developing colorectal cancer by expanding the number of genetic markers, commonly called Single Nucleotide Polymorphisms (SNPs) used as an important element of GTG’s geneType Risk Assessment Test for colorectal cancer.
Colorectal cancer risk stratification can be crucial to improving screening and risk-reducing recommendations, and consequently does better than a one-size-fits-all screening regimen. Current screening guidelines in the UK, USA and Australia focus solely on family history and age for risk prediction. Unfortunately, the vast majority of the population do not have any hereditary or familial history and would remain unaware that they could be at elevated risk of developing colorectal cancer. GTG’s geneType Risk Assessment test is directly targeting this population to enable the early identification of colorectal cancer.
An earlier publication in 2021 by GTG’s science team titled “Ability of known colorectal cancer susceptibility SNPs to predict colorectal cancer risk: A cohort study within the UK Biobank” was an important validation of the geneType Risk Assessment test. The test uses 45 SNPs combined with family history offering a significant improvement in risk stratification particularly with the potential to be used in broad based population screening.
GTG’s Director of Clinical and Scientific Affairs, Dr Erika Spaeth, noted, “By expanding the panel of SNPs in our polygenic risk from 45 to 144 we are able to show a significant improvement in identifying patients in the top risk category. GTG is committed to continuous product improvement with the goal of positively impacting a patient’s screening and risk-reduction opportunities.”
Simon Morriss, CEO of GTG, added, “The health economics demonstrated by our geneType breast cancer risk assessment test Budget Impact Model provide a pathway to reimbursement for the company’s enhanced risk assessment test for colorectal cancer. The team at GTG continue to build a strong, relevant portfolio of risk assessment tests that enable patients, or those individuals with an increased risk of developing disease, to navigate treatment options, implement disease prevention strategies and make lifestyle changes to reduce the risk of disease development.”
Authorised for release by the board of directors of Genetic Technologies Limited.
M: +61 438 630 411
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
Forward Looking Statements
This press release may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.